A 72-year-old man with a history of NSAID use presents with melena and is found to have a bleeding duodenal ulcer on upper endoscopy. Regarding the pathophysiology and management of peptic ulcer bleeding, all of the following are correct EXCEPT:

Explanation

## Peptic Ulcer Disease Pathophysiology and Management ### NSAID-Induced Ulcers **Key Point:** NSAIDs inhibit both COX-1 and COX-2 enzymes, reducing prostaglandin (PGE~2~ and PGI~2~) synthesis. Prostaglandins are critical for: - Gastric mucus secretion - Bicarbonate secretion - Mucosal blood flow - Epithelial cell proliferation Loss of these protective mechanisms leads to mucosal injury and ulceration [cite:Harrison 21e Ch 297]. ### Helicobacter pylori Infection — The Critical Error **Warning:** The statement about H. pylori "eradicating the gastric mucosa-associated lymphoid tissue (MALT)" is **INCORRECT** and represents a fundamental misunderstanding of H. pylori pathogenesis. **High-Yield:** H. pylori does NOT eradicate MALT; rather, it **induces and activates** MALT. The correct sequence is: | Step | Mechanism | Outcome | |------|-----------|----------| | 1 | H. pylori colonizes gastric mucosa | Chronic infection established | | 2 | Bacterial antigens activate MALT | MALT lymphocytes proliferate | | 3 | Chronic inflammation (Th1/Th17) | Mucosal damage, atrophy, metaplasia | | 4 | Ulceration or intestinal metaplasia | Duodenal ulcer or gastric cancer risk | **Clinical Pearl:** H. pylori is a **pro-inflammatory stimulus** that drives MALT activation and proliferation, not eradication. In fact, H. pylori-associated MALT lymphoma arises from this aberrant MALT activation. Eradication of H. pylori causes MALT to regress. ### Acid Suppression and PPI Therapy **Key Point:** Proton pump inhibitors (omeprazole, lansoprazole, pantoprazole) irreversibly inhibit the H^+^/K^+^-ATPase pump, reducing gastric acid secretion. They increase intragastric pH above 6, which: - Promotes ulcer healing - Allows platelet aggregation and clot stabilization - Inactivates pepsin PPIs are the gold standard for ulcer healing and are superior to H2-receptor antagonists [cite:KD Tripathi 8e Ch 48]. ### Endoscopic Hemostasis **Key Point:** Endoscopic therapy for bleeding peptic ulcers combines two modalities: - **Epinephrine injection** (1:10,000 dilution) causes local vasoconstriction and tamponade - **Thermal therapy** (heater probe, argon plasma coagulation) or **mechanical therapy** (clips, bands) achieves permanent hemostasis Combined therapy achieves hemostasis in >90% of cases and is the standard of care [cite:Harrison 21e Ch 297]. ### Comparison Table: Peptic Ulcer Etiology | Etiology | Mechanism | MALT Role | Management | |----------|-----------|-----------|-------------| | **H. pylori** | Chronic inflammation + acid | MALT **activated** → proliferation | Eradication therapy | | **NSAID** | COX inhibition → ↓ PG | MALT not primarily involved | PPI + NSAID cessation | | **Zollinger-Ellison** | Gastrin overproduction | MALT not involved | PPI (high-dose) | ### Summary Diagram ```mermaid flowchart TD A[H. pylori Infection]:::outcome --> B[Colonizes gastric mucosa]:::action B --> C[Activates MALT lymphocytes]:::action C --> D[Chronic Th1/Th17 inflammation]:::action D --> E[Mucosal damage & ulceration]:::outcome F[Eradication therapy]:::action --> G[MALT regresses]:::outcome H[NSAIDs]:::outcome --> I[Inhibit COX-1/COX-2]:::action I --> J[Reduce prostaglandins]:::action J --> K[Loss of mucosal protection]:::action K --> L[Ulceration]:::outcome ```